Nadofaragene firadenovec-vncg (Adstiladrin) — intravesical suspension coverage criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, authorization, dosing, and distribution considerations for intravesical nadofaragene firadenovec-vncg (Adstiladrin) for adults with BCG-unresponsive non‑muscle invasive bladder cancer (CIS with or without papillary tumors) under Blue Cross NC.
Added revenue codes 0891 and 0892 as applicable to the policy HCPCS code(s).
Added Gene/Cellular Therapy distribution channel management language according to benefit booklet for clarity.
Coverage Criteria for Nadofaragene firadenovec-vncg (Adstiladrin)
Initial Therapy
Covered when ALL of the following are met:
Initial Criteria for Approval
- Age: Patient is 18 years of age or older
- Diagnosis of non-muscle invasive bladder cancer (NMIBC)
- CIS: Carcinoma in situ (CIS)
BCG-unresponsive
- BCG-unresponsive option a: BOTH: at least five of six doses of an initial induction course AND ONE of: at least two of three doses of maintenance therapy OR at least two of six doses of a second induction course; AND persistent disease following BCG therapy OR disease recurrence after an initial tumor-free state following BCG therapy
- BCG-unresponsive option b: T1 disease following a single induction course of BCG
- Resection: All resectable disease (Ta and T1 components) has been removed
- No extra-vesical or invasive disease: No extra-vesical (urethra, ureter, or renal pelvis), muscle invasive, or metastatic urothelial carcinoma
- Specialist involvement: Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, urologist) or has consulted with such a specialist
- Immunocompetent: Patient is NOT immunocompromised and does NOT have immunodeficiency
- Contraindications: Patient does NOT have any FDA-labeled contraindications to the requested agent
- Dosing within label: Requested dose is within FDA-labeled dosing for the indication, and the requested quantity does NOT exceed the maximum units allowed for the duration of approval
Continuation Therapy
Covered for continuation when ALL of the following are met:
Continuation Criteria for Approval
- Prior approval history: Patient was previously approved through Blue Cross NC initial criteria OR would have met initial criteria at the time they started therapy
- Clinical benefit: Patient has demonstrated continued clinical benefit while receiving treatment, as shown by tumor response or lack of disease progression and an acceptable toxicity profile
- Specialist involvement: Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, urologist) or has consulted with such a specialist
- Immunocompetent: Patient is NOT immunocompromised and does NOT have immunodeficiency
- Contraindications: Patient does NOT have any FDA-labeled contraindications to the requested agent
- Dosing within label: Requested dose is within FDA-labeled dosing for the indication and does NOT exceed the maximum units allowed for the duration of approval
Coverage excludes patients with extra‑vesical disease — specifically involvement of the urethra, ureter, or renal pelvis — as well as those with muscle‑invasive or metastatic urothelial carcinoma. Documentation of absence of these disease sites is required in the medical record.
Nadofaragene firadenovec‑vncg is not covered for use in patients who do not meet the policy’s BCG‑unresponsive definitions, in patients with unresected Ta or T1 disease, in patients who are immunocompromised or have immunodeficiency, or in patients with any FDA‑labeled contraindication to the agent. Medical record documentation must demonstrate the patient meets the BCG‑unresponsive criteria, that all resectable Ta/T1 disease has been removed, and that the patient is immunocompetent and free of contraindications.
Coding and Quantity Limits
| J9029 | Nadofaragene firadenovec‑vncg intravesical suspension (per policy) |
| 0891 | Special Processed Drugs - FDA Approved Cell Therapy (revenue) |
| 0892 | Special Processed Drugs - FDA Approved Gene Therapy (revenue) |
Provider Actions, Authorization, and Documentation
Prior authorization required; coordinate specialty pharmacy distribution with Blue Cross NC
Prior authorization is required for nadofaragene firadenovec‑vncg (Adstiladrin). When submitting a request, include documentation that the patient meets the initial medical necessity criteria. For certain gene and cellular therapies, distribution from a specialty pharmacy provider may be required; contact Blue Cross NC to coordinate distribution and coverage.
- Prior authorization must document that the patient meets all initial criteria.
- Specialty pharmacy distribution channel management may be required; contact Blue Cross NC to coordinate.
No explicit step therapy — BCG‑unresponsive status required
There is no formal step therapy sequence specified in this policy. The documented requirement is that the patient be BCG‑unresponsive per the policy’s defined criteria (prior BCG exposure and failure conditions).
- Patient must meet the policy definition of BCG‑unresponsive (see criteria).
Required medical record documentation for initial and continuation approval
Include medical record documentation showing the diagnosis and all clinical elements required for medical necessity: NMIBC with carcinoma in situ, BCG‑unresponsive status per the policy subcriteria, removal of all resectable Ta/T1 disease, absence of extra‑vesical/muscle invasive/metastatic disease, specialist prescriber or consultation, immunocompetence, and absence of any FDA‑labeled contraindications.
- Diagnosis: non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
- BCG‑unresponsive documentation per policy (induction/maintenance or second induction timing, persistent or recurrent disease, or T1 after single induction).
- Operative/pathology or procedure notes documenting removal of all resectable Ta/T1 disease.
- Evidence the prescriber is a specialist or that a specialist was consulted.
- Documentation that the patient is not immunocompromised and has no FDA‑labeled contraindications.
- For continuation: documentation of continued clinical benefit (tumor response or lack of progression) and acceptable toxicity.
Document FDA‑labeled dosing and quantity; adhere to maximum units
Document that the requested dose and quantity conform to the FDA‑labeled dosing and the policy maximum units. The FDA‑recommended instilled dose is 75 mL at a concentration of 3 x 10^11 viral particles/mL given intravesically once every 3 months, and the policy lists a maximum units value of 5.
- FDA‑recommended dosing: 75 mL at 3 x 10^11 vp/mL instilled once every 3 months.
- HCPCS code: J9029; Maximum Units = 5.
Denial risk if initial medical necessity criteria are not fully documented
Requests that do not document the patient meets all initial medical necessity criteria are at risk for denial. Missing required documentation includes age ≥18, diagnosis of NMIBC with CIS, BCG‑unresponsive status per the defined subcriteria, removal of all resectable Ta/T1 disease, absence of extra‑vesical/muscle invasive/metastatic disease, specialist prescriber/consultation, immunocompetence, and absence of FDA‑labeled contraindications.
- All initial criteria listed in the policy must be documented (age, diagnosis, BCG‑unresponsive, resection of resectable disease, disease extent, specialist involvement, immunocompetence, contraindications).
- Incomplete documentation may result in denial of the request.
Definitions
Background
Nadofaragene firadenovec‑vncg (Adstiladrin) is an intravesical gene therapy indicated for adults with high‑risk BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ (CIS), with or without papillary tumors. The agent is administered by intravesical instillation and dosing should follow the FDA‑labeled regimen; requests must document prior BCG exposure and the specific BCG‑unresponsive condition (persistent or recurrent disease after specified BCG dosing or T1 disease following induction), as well as removal of all resectable Ta/T1 disease and absence of extra‑vesical, muscle‑invasive, or metastatic disease.
Revision History and Policy Changes
Added revenue codes 0891 and 0892 as applicable to the policy HCPCS code(s) and added Gene/Cellular Therapy distribution channel management language; policy notification issued 2026-02-01 for 2026-04-01 effective date.
Minor formatting updates to criteria without change to policy intent.
Added HCPCS code J9029 to dosing reference table and removed codes C9399, J3490, J3590, and J9999 (termed 2023-06-30); updated maximum units based on code definition.
Original medical policy criteria issued.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.